| Comparison with 99mTc MDP Bone Scintigraphy and Whole body 18FDG PET for the Evaluation of Bone metastases in Patients with Lung Cancer. |
|
Jae Ho Chung, Moo Suk Park, Chang Hoon Hahn, Jin Wook Moon, Young Sam Kim, Se Kyu Kim, Joon Chang, Jong Doo Lee, Sung Kyu Kim |
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. skkimpul@yumc.yonsei.ac.kr
2Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea.
3The Institute of Chest Diseases, Yonsei University College of Medicine, Seoul, Korea.
4Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.
5Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea. |
|
|
| Abstract |
BACKGROUND
99mTechnetium methylene diphosphonates(99mTc MDP) bone scintigraphy is current method of choice for the detection of bone metastases, but whole body 18F-fluoro-deoxy-D-glucose positron emission tomography(18FDG PET) offers superior spatial resolution and improved sensitivity. So we compared whole body 18FDG PET with 99mTc MDP bone scintigraphy in patients with skeletal metastases from lung cancer. PATIENTS AND METHODS: Ninety-two patients with lung cancer taken 18FDG PET together with a 99mTc MDP bone scintigraphy within 1 month between March 2000 and March 2003 were investigated retrospectively. RESULTS: The sensitivity, specificity and accuracy of the 99mTc MDP bone scintigraphy versus 18FDG PET for the detection of bone metastases in lung cancers were 59% vs 82%, 71% vs 94%, and 68% vs 91%, respectively. In the diagnosis of bone metastases from lung cancer, 18FDG PET was statistically superior to 99mTc MDP bone scintigraphy in its specificity and accuracy(P<0.0001). CONCLUSIONS: Whole body 18FDG PET may be useful in detecting bone metastases among patients with lung cancer. |
| Key Words:
18FDG PET, 99mTc MDP bone scintigraphy, Bone metastases, Lung cancer |
|
PDF Links
Full text via DOI
Download Citation
